成人慢性肾脏病患者的外显子组优先策略:一项队列研究
该前瞻性队列研究自2018年9月起对成人不明原因肾病或临床怀疑遗传性肾病者行外显子组测序(ES)作为一线探索,538例中127例(24%)获得分子诊断,涉及47种单基因病;作者开发了4变量临床评分预测分子诊断概率(AUC 0.726,95%CI 0.670-0.782),认为ES可作为表型贫乏或不典型成人慢性肾脏病的一线探索,但评分需外部验证。
要点
- ES在成人CKD队列中诊断率为24%(127/538),共47种单基因病。
- 8种单基因病占遗传诊断的52%,98%(125/127)遗传信息有重大临床意义。
- 4变量临床评分预测分子诊断概率AUC 0.726(95%CI 0.670-0.782)。
核心结论
- 本研究强化了ES作为成人慢性肾脏病患者一线探索的作用,这些患者表型常贫乏且不典型。
- 作者认为其临床评分虽需外部验证,但可能有助于在成人中实施肾脏基因组学。
研究设计与样本
- 自2018年9月起,前瞻性对成人不明原因肾病和/或临床怀疑遗传性肾病者行ES作为一线宽松探索,并用同一检测分析拷贝数变异。
- 共对538例患者行ES,其中127例获得分子诊断(诊断率24%),涉及47种不同单基因病。
主要发现
- 分子诊断见于538例测序患者中的127例(诊断率24%),涵盖47种不同单基因病。
- 8种单基因病(17%[8/47])占遗传诊断的52%。
- 98%(n=125/127)的患者中遗传信息被报告有重大临床意义。
- 作者开发了4变量临床评分预测获得分子诊断的概率,AUC为0.726(95%CI 0.670-0.782)。
关键数值与推荐
- 诊断率24%(127/538)。
- 8种单基因病占遗传诊断52%,占单基因病种类的17%(8/47)。
- 临床评分AUC 0.726(95%CI 0.670-0.782),4个变量。
- 遗传信息有重大临床意义者占98%(125/127)。
临床怎么用
- 作者认为ES可作为表型常贫乏且不典型的成人慢性肾脏病患者的一线探索。
- 作者认为其临床评分虽需外部验证,但可能有助于在成人中实施肾脏基因组学。
局限性
- 作者指出其临床评分需要外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Exome sequencing (ES) has widened the field of nephrogenomics in adult nephrology. In addition to reporting the diagnostic yield of ES in an adult cohort study, we investigated the clinical implications of molecular diagnosis and developed a clinical score to predict the probability of obtaining positive result. METHODS: From September 2018 we have used ES to prospectively perform a first-tier liberal exploration of adult nephropathies of unknown origin and/or when a genetic kidney disease was clinically suggested. We also analyzed copy number variant using the same assay. RESULTS: Molecular diagnosis was made in 127 of 538 patients sequenced (diagnostic yield: 24%), comprising 47 distinct monogenic disorders. Eight of these monogenic disorders (17% [8/47]) accounted for 52% of genetic diagnoses. In 98% (n = 125/127) of the patients, the genetic information was reported to have major clinical implications. We developed a 4-value clinical score to predict the probability of obtaining a molecular diagnosis (area under the receiver operating characteristics curve [AUC] 0.726 [95% confidence interval: 0.670-0.782]) (available at http://allogenomics.com/score). CONCLUSION: This study reinforces the role of ES as a first-tier exploration for adult chronic kidney disease patients in whom phenotypes are often poor and atypical. Although external validation is required, our clinical score could be a useful tool for the implementation of nephrogenomics in adults.
引用
- Doreille A, Lombardi Y, Dancer M, et al. Exome-First Strategy in Adult Patients With CKD: A Cohort Study. Kidney Int Rep. 2022. PMID: 36938085. doi:10.1016/j.ekir.2022.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。